A small German company called CureVac is on the cusp of announcing the results of its late-stage clinical trial, and unlike the Moderna and Pfizer-BioNTech vaccine, the RNA vaccine made by CureVac doesn't need a deep freezer
A volunteer receives a dose of CureVac vaccine or a placebo during a study by the German biotech firm CureVac as part of a testing for a new vaccine against the coronavirus disease (COVID-19), in Brussels, Belgium March 2021; Image: Reuters/Yves Herman
©2019 New York Times News Service